Blogindlæg

Advisory boardet kan hjælpe ledelsesteamet med at realisere større succes ved at give adgang til erfaring og netværk, som teamet ofte ikke selv ville have ressourcerne til at udvikle. Mindre end 6% af startups og små til mellemstore virksomheder har et advisory board, men dem der har, generer tre gange så stor omsætning og er dobbelt så produktive.

With help from CVX Ventures, ContentAvenue haven added the CVX Partner Grith Okholm Skaarup as a strategic advisor.

CVX Ventures invests in the Swedish B2B SaaS company Bookboost. Bookboost grew 5 times over the past 12 months. The B2B SaaS company will use the investment to expand their sales team and invest further in product development.

The robotics company Self have recruited CVX Partner Eskild Ebbesen as new advisor. CVX Ventures have helped Self in their recruitment process which now brings the company new competencies from the Olympic gold medalist and Cand.Scient in sports physiology.

The new advisors will bring a variant of different skills to ProRoom. The combination of the three CVX partners will play a part in the company’s growth and expansion in future business.

DTU spinout, secures convertible loans from Vækstfonden and other investors for their patented laser spectrometer technology. The technology is significantly smaller and cheaper than competitors, with a wide range of applications in academia and industrial sectors. The funds will be used to expand operations and bring the technology to a wider range of customers.

CVX Ventures helped provide Drone Systems, with a new advisor with knowledge in the field of district heating. The advisor will work closely together with Drone Systems optimizing drone technology to inspect and maintain district heating systems.

Adiso’s platform is launching a cutting-edge technology to provide personalized plant recommendations to consumers based on their specific needs. The method takes into account factors such as stress relief, and other human benefits of plants, making it easy for consumers to find the perfect plants to meet their needs.

Amolyt specializes in developing therapeutic peptides for rare hormone diseases and related diseases. Although rare diseases only affect a small portion of the population, they can have serious consequences for patients. Amolyt therefore focuses on developing effective treatments for these patients.

Metagenomi is still in the preclinical phase, but despite this, it has managed to attract 275 million dollars in a recently completed series B financing round. Initially, Metagenomi raised 175 million dollars, but an expansion secured the company a total of 275 million dollars, with Novo Holdings leading the expansion round for 100 million dollars.